MTG-022 Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics
for the Diagnosis and Personalized Management of Patients. Under the MTG-022
master protocol are two SOP studies: MT1410-A and MT9920.
Sponsor: The MT Group
Principal Investigator: Jeffery Pelton, MD
MT1410-A-Cancer Cohort: This study is designed to evaluate molecular characteristics in the blood
samples of patients with Bladder, Brain, Colorectal, Esophageal, Gastric,
Kidney, Liver, Ovarian, Pancreas, and Prostate Cancer. These samples will
be used immediately or stored in a “Biobank”. Researchers
will use these samples to try to develop new drugs or treatments or tests,
as well as to study how individual differences may affect how drugs work.
MT9920 SOP:This study is designed to evaluate biomarkers in samples of patients with
cancer. In many cases, the investigation is to identify novel markers
to create new anti-cancer therapies and companion diagnostics. The biomarkers
could be present in plasma, serum, or the tumor tissue itself. In addition,
some tumors will be used in a culture environment to determine the efficacy
of novel anti-cancer drugs and some tissues will be mined to isolate,
purify, and culture tumor infiltrating lymphocytes, to evaluate immune
reactivity in patients.
Sponsor: University of Nebraska Medical Center
Principal Investigator for Breast Registry: Darlene K. Blanchard, MD
Principal Investigator for Thoracic Registry: J. Timothy Sherwood, MD
Principal Investigator for Head & Neck Registry: Dr. Stephen Bakos, MD, PhD
Purpose of this registry: The data registry,
(iCaRe2), will provide core support services for multi-disciplinary research for
cancer. It is the hope that future research using information from this
registry will lead to improved diagnosis, prevention, and treatment of cancer.
Click here for more information on the Breast Registry.
Click here for more information on the Thoracic Registry.
Click here for more information on the Head & Neck Registry.